Halozyme Therapeutics HALO Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's restricted cash?
- Halozyme Therapeutics (HALO) reported restricted cash of $2.26M in Q1 2026.
- What is the long-term trend for Halozyme Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's restricted cash has grown at a 39.1% compound annual growth rate (CAGR), from $500K to $2.6M.
- What does restricted cash mean?
- Cash that is legally set aside and cannot be used for general business operations.
- How do you interpret restricted cash?
- An increase may indicate higher collateral requirements or specific contractual obligations, while a decrease suggests the release of funds back into general liquidity.
- How does restricted cash compare across companies?
- Varies significantly by industry based on debt covenants and regulatory requirements.